ReviewAntibiotics (Basel, Switzerland)2016
Sub-Optimal Treatment of Bacterial Biofilms.
Review in Antibiotics (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Bacterial outer membrane vesicles: a smart platform for biomedical applications.Cell communication and signaling : CCS · 2026Review
- Z‑Amino Acids Present Innovative Antimicrobial and Antibiofilm Properties against Methicillin-Susceptible and -ResistantACS omega · 2026Article
- Artificial intelligence applications in biofilm research: computational approaches for biofilm analysis and antimicrobial prediction.Frontiers in microbiology · 2026Review
- In vitro assessment of the osteogenic and antibacterial capabilities of Mg-MOF particles with encapsulated Levofloxacin within polydopamine.Scientific reports · 2025Article
- A Review Vancomycin Role in Gram Positive Biofilm-Associated Infections: Challenges and Emerging Solutions.Therapeutics and clinical risk management · 2025Review
- Fighting fibrin with fibrin: Vancomycin delivery into coagulase-mediated Staphylococcus aureus biofilms via fibrin-based nanoparticle binding.Journal of biomedical materials research. Part A · 2024Article
- Antimicrobial Sub-MIC induces Staphylococcus aureus biofilm formation without affecting the bacterial count.BMC infectious diseases · 2024Article
- Subminimum Inhibitory Concentrations Tetracycline Antibiotics Induce Biofilm Formation in Minocycline-ResistantACS infectious diseases · 2024Article
- Agar and agarose used for Staphylococcus aureus biofilm cultivation impact fluoroquinolone tolerance.Journal of applied microbiology · 2024Article
- Review
- Membrane fluidity homeostasis is required for tobramycin-enhanced biofilm inMicrobiology spectrum · 2024Article
- Antibiotic-Induced Biofilm Formations in Pseudomonas aeruginosa Strains KPW.1-S1 and HRW.1-S3 are Associated with Increased Production of eDNA and Exoproteins, Increased ROS Generation, and Increased Cell Surface Hydrophobicity.Current microbiology · 2023Article
- Quarter-wise proportion and beta-lactam resistance rate of bovine mastitis associated-Heliyon · 2023Review
- Host-Defense-Peptide-Mimicking β-Peptide Polymer Acting as a Dual-Modal Antibacterial Agent by Interfering Quorum Sensing and Killing Individual Bacteria Simultaneously.Research (Washington, D.C.) · 2023Article
- Antibiotics-Free Compounds for Chronic Wound Healing.Pharmaceutics · 2022Review
- Influence of Sub-Inhibitory Dosage of Cefotaxime on Multidrug ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Novel colistin-EDTA combination for successful eradication of colistin-resistant Klebsiella pneumoniae catheter-related biofilm infections.Scientific reports · 2021Article
- Article
- Emerging Concern for Silver Nanoparticle Resistance inFrontiers in microbiology · 2021Review
- Clinical Biofilm Ring TestPathogens (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial biofilm is an emerging clinical problem recognized in the treatment of infectious diseases within the last two decades. The appearance of microbial biofilm in clinical settings is steadily increasing due to several reasons including the increased use of quality of life-improving artificial devices. In contrast to infections caused by planktonic bacteria that respond relatively well to standard antibiotic therapy, biofilm-forming bacteria tend to cause chronic infections whereby infections persist despite seemingly adequate antibiotic therapy. This review briefly describes the responses of biofilm matrix components and biofilm-associated bacteria towards sub-lethal concentrations of antimicrobial agents, which may include the generation of genetic and phenotypic variabilities. Clinical implications of bacterial biofilms in relation to antibiotic treatments are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.